Skip to main content
Brain+ A/S logo

Brain+ A/S — Investor Relations & Filings

Ticker · BRAINP ISIN · DK0061670205 LEI · 9845007708709CEGD845 ST Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 2 across all filing types
Latest filing 2023-05-10 Regulatory Filings
Country DK Denmark
Listing ST BRAINP

About Brain+ A/S

https://www.brain-plus.com/

Brain+ A/S is a health technology company that develops digital therapeutics for the detection and treatment of cognitive decline, primarily in individuals with dementia and Alzheimer's disease. The company focuses on digitalizing Cognitive Stimulation Therapy (CST), a clinically-proven, non-pharmacological treatment recommended by global health organizations. Its primary product is the Ayla platform, a digital CST assistant designed for healthcare providers. Ayla offers standardized, adaptable, and validated therapeutic activities to help delay cognitive decline, improve communication skills, and enhance the quality of life for patients, while also increasing efficiency for care providers by reducing preparation time.

Recent filings

Filing Released Lang Actions
Approval of Supplementary Prospectus No. 1 for BRAIN+ A/S; Derivatives
Regulatory Filings Classification · 1% confidence The document is a 'Supplement to EU Growth prospectus' for Brain+ A/S. It details specific adjustments to a previously published prospectus following the release of the company's 2022 audited annual report. It updates financial figures, working capital statements, and references within the original prospectus. As this is a formal regulatory supplement to a securities offering document (prospectus) and not a standalone annual report, earnings release, or announcement, it falls under the category of regulatory filings related to capital raising and securities offerings.
2023-05-10 English
Approval of prospectus for BRAIN+ A/S; Derivatives
Capital/Financing Update Classification · 1% confidence The document is a formal 'EU growth Prospectus' for Brain+ A/S, detailing a rights issue of units (shares and warrants). It includes regulatory approval from the Danish Financial Supervisory Authority, terms of the offering, risk factors, and business strategy. While it contains financial information, it is primarily a capital-raising document (prospectus) rather than an annual report or earnings release. Under the provided categories, 'CAP' (Capital/Financing Update) is the most accurate classification for a prospectus related to a rights issue.
2023-04-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.